Premium
Botulinum toxin type A in the treatment of Raynaud's phenomenon
Author(s) -
Habib S. Meelad,
Brenninkmeijer Elian E. A.,
Vermeer Maarten H.,
VriesBouwstra Jeska K.,
Velthuis Peter J.
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14182
Subject(s) - medicine , dermatology , limiting , botulinum toxin , raynaud disease , surgery , mechanical engineering , engineering
Raynaud's phenomenon is a vasospastic disorder clinically characterized by cold or stress‐induced discoloration of the skin, pain and ulcers of the fingers or toes. Although this phenomenon might be self‐limiting, there is a subgroup of patients requiring a therapeutic approach. The majority of patients do well on conservative measures; however, there is also a subgroup requiring systemic treatment. The efficacy of these systemic treatments is currently not thoroughly investigated. Furthermore, no uniform guidelines exist regarding the choice for a treatment option. In the past several years, several reports have shown the benefits of botulinum toxin for the treatment of Raynaud's phenomenon. In this case series, we report our experience with botulinum toxin type A in the treatment of Raynaud's phenomenon.